Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics Inc (NASDAQ: PSTV) is a clinical-stage biopharmaceutical company pioneering targeted radiotherapeutics for challenging cancers. This news hub provides investors and medical professionals with essential updates on clinical trials, regulatory developments, and strategic partnerships.
Access timely reports on PSTV's innovative CNS cancer therapies including rhenium (186Re) obisbemeda for glioblastoma and leptomeningeal metastases. Track progress across multiple development stages while staying informed about financial updates and manufacturing collaborations that support the company's pipeline.
Our curated collection features earnings announcements, trial result disclosures, FDA communications, and partnership expansions. All content is verified through primary sources to ensure accuracy for investment research and clinical practice decisions.
Bookmark this page for streamlined access to PSTV's latest scientific advancements and corporate developments. Check regularly for critical updates impacting the neuro-oncology treatment landscape and the company's position within precision radiotherapy markets.
Plus Therapeutics (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on targeted radiotherapeutics for CNS cancers, has regained compliance with Nasdaq listing requirements. The company received confirmation from Nasdaq on August 22, 2025, verifying compliance with two key criteria: maintaining a market value of listed securities above $35 million and stockholders' equity exceeding $2.5 million.
As a result, PSTV has been granted an extended grace period until November 12, 2025, to meet the $1.00 bid price requirement, replacing the previous September 8 deadline. The company remains under panel monitoring for the Equity Standard through August 22, 2026.
Plus Therapeutics (NASDAQ:PSTV) announced positive results from its ReSPECT-LM Phase 1 trial for REYOBIQ™ in treating leptomeningeal metastases (LM). The trial, involving 29 subjects across 6 cohorts, demonstrated significant efficacy with a 76% radiographic and 87% clinical response rate through day 112.
Key outcomes include 100% reduction in CSF tumor cells at day 28, with five of seven patients showing >80% tumor cell reduction surviving at least one year. The median overall survival reached 9 months, substantially better than the typical 4-month survival rate. The study established a recommended Phase 2 single dose of 44.1 mCi, with no dose-limiting toxicities in cohorts 1-4 and manageable safety profile in higher doses.
[ "Clinical benefit rate exceeded 75% in 3 key outcome measures", "Median overall survival of 9 months vs typical 4 months in literature", "100% reduction in CSF tumor cells observed at day 28", "Favorable safety profile with majority of adverse events being Grade 1 and 2", "Five of seven patients with >80% tumor cell reduction survived at least 1 year" ]Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company focused on targeted radiotherapeutics for CNS cancers, has successfully addressed its Nasdaq listing compliance concerns. The company reported stockholders' equity of $3 million as of June 30, 2025, exceeding the minimum requirement of $2.5 million under Nasdaq Listing Rule 5550(b)(1).
This development follows a period of non-compliance identified on June 3, 2025, which led to a hearing before the Nasdaq Hearings Panel on July 15, 2025. The Panel granted Plus an extension to demonstrate compliance, and the company's recent Form 10-Q filing on August 14, 2025, confirms its return to compliance with the Equity Rule.
Plus Therapeutics (NASDAQ:PSTV) reported Q2 2025 financial results and significant progress in its CNS cancer treatment programs. The company achieved net income of $5.2 million ($0.02 per share), compared to a net loss of $2.9 million in Q2 2024, primarily due to derivative instruments valuation changes. Cash position strengthened to $6.9 million as of June 30, 2025.
Key developments include the initiation of the REYOBIQ dose optimization trial for leptomeningeal metastases treatment and FDA clearance for pediatric brain cancer treatment. The company also announced the commercial launch of its CNSide CSF assay platform in Texas, targeting a $6 billion U.S. market, with plans for national expansion. Additionally, Plus completed restructuring of its $15 million equity financing and received a $1.6 million CPRIT grant payment.
Plus Therapeutics (NASDAQ:PSTV) presented positive data from their CNSide® Cerebrospinal Fluid (CSF) Assay Platform at the 2025 SNO/ASCO CNS Metastases Conference. The retrospective analysis, involving 613 CNSide assays from 218 patients across 5 institutions, demonstrated significant capabilities in detecting and monitoring leptomeningeal metastases (LM).
Key findings include 67% detection rate of CSF tumor cells, with notable observations of immunocytochemistry and FISH probe detection changes in patients with multiple CSF draws. The platform showed 2.8 times higher diagnostic sensitivity compared to standard CSF cytology and influenced clinical management decisions in over 90% of LM cases.
Plus Therapeutics (NASDAQ:PSTV) announced the commercial launch of its CNSide® diagnostic platform in Texas starting August 2025. The CNSide cerebrospinal fluid assay platform will initially focus on NCI-Designated Cancer Centers, including UT Southwestern, MD Anderson Cancer Center, and other major healthcare systems.
The CNSide platform is designed to identify tumor cells that have metastasized to the central nervous system, demonstrating 92% sensitivity and 95% specificity. The diagnostic tool has influenced treatment decisions in over 90% of cases and has been validated through more than 11,000 tests performed at over 200 U.S. cancer institutions since 2020.
Plus Therapeutics (NASDAQ:PSTV) has received a $1.6 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT) as part of a previously awarded $17.6 million grant. The company expects an additional $6 million in funding over the next 12 months.
The non-dilutive financing will support the clinical development of REYOBIQ™ for the ReSPECT-LM dose optimization trial and the development of CNSide LM diagnostic test. CPRIT, the second-largest public cancer research funder globally, along with active NIH and DoD grants, demonstrates strong institutional support for Plus Therapeutics' clinical programs.
Plus Therapeutics (NASDAQ:PSTV) announced it will present final results from its ReSPECT-LM clinical trial for REYOBIQ™ in treating leptomeningeal metastases (LM) at the 2025 SNO/ASCO CNS Metastases Conference. The presentation will be delivered by Dr. Andrew Brenner on August 15, 2025, focusing on Phase 1 dose escalation study results for safety and efficacy.
The company will also host an educational symposium titled "Reimagining Your Approach to Leptomeningeal Metastases" on August 14, featuring presentations from five leading neuro-oncologists. Previously reported data showed encouraging safety profiles and response signals in LM patients. Additionally, Plus Therapeutics' subsidiary, CNSide Diagnostics, will present two separate presentations at the conference.
Plus Therapeutics (NASDAQ:PSTV) announced two upcoming presentations featuring its CNSide Cerebrospinal Fluid (CSF) Assay Platform at the SNO/ASCO CNS Metastases Conference, scheduled for August 14-16, 2025, in Baltimore, MD.
The presentations, both delivered by Dr. Priya Kumthekar, will focus on CSF tumor cell detection and quantification in patients with leptomeningeal disease. The diagnostic platform's capabilities in enhancing CNS metastases management and supporting therapies like REYOBIQ™ in the ReSPECT-LM dose optimization trial will be highlighted.
Plus Therapeutics (NASDAQ:PSTV) has announced the successful treatment of initial patients in its ReSPECT-LM dose optimization trial for REYOBIQ™ (rhenium Re186 obisbemeda) targeting leptomeningeal metastases (LM). The trial follows promising Phase 1 results where 5 out of 7 patients achieved over 80% reduction in LM tumor cells and survived at least one year post-treatment.
The dose optimization study, supported by a $17.6 million CPRIT grant, aims to determine optimal dosing for efficacy and safety in alignment with FDA's Project Optimus. The company expects to complete Cohort 1 enrollment by year-end and plans to present additional Phase 1 data at the SNO/ASCO CNS Metastases Conference in August 2025.
FAQ
What is the current stock price of Plus Therapeutics (PSTV)?
What is the market cap of Plus Therapeutics (PSTV)?
